PuSH - Publikationsserver des Helmholtz Zentrums München

Bölükbas, D.A. ; Meiners, S.

Lung cancer nanomedicine: Potentials and pitfalls.

Nanomed. 10, 3203-3212 (2015)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
Lung cancer is by far the most common cause of cancer-related deaths in the world. Nanoparticle-based therapies enable targeted drug delivery for lung cancer treatment with increased therapeutic efficiency and reduced systemic toxicity. At the same time, nanomedicine has the potential for multimodal treatment of lung cancer that may involve 'all-in-one' targeting of several tumor-associated cell types in a timely and spatially controlled manner. Therapeutic approaches, however, are hampered by a translational gap between basic scientists, clinicians and pharma industry due to suboptimal animal models and difficulties in scale-up production of nanoagents. This calls for a disease-centered approach with interdisciplinary basic and clinical research teams with the support of pharma industries.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Korrespondenzautor
Schlagwörter Active Targeting ; Clinical Studies ; Lung Cancer Therapy ; Nanomedicine ; Nanoparticle ; Tumor Mouse Model
ISSN (print) / ISBN 1743-5889
e-ISSN 1748-6963
Zeitschrift Nanomedicine
Quellenangaben Band: 10, Heft: 21, Seiten: 3203-3212 Artikelnummer: , Supplement: ,
Verlag Future Medicine
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Lung Health and Immunity (LHI)